PlaqueTec recruits first ten patients in BIOPATTERN trial

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

RP-3 by Replimune for Gastrointestinal Tract Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Gastrointestinal Tract Cancer.

November 18, 2023

Data: Key to Unlocking Better Behavioral Health Outcomes

Sarah Reilly, SVP, Product and Strategy, Lucet The growing demand for behavioral healthcare in America is putting a serious strain on both payers and providers

July 11, 2023

Treating Male Sexual Partners May Prevent Bacterial Vaginosis Recurrence

Treating male sexual partners and women with bacterial vaginosis was better than treating women alone. Unlike past trials, both oral and topical antibiotic partner treatment

March 6, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.